Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.

Abstract: Tracers for oil recovery, particularly fluorescent nanotracers conservative in aqueous phases. The tracer comprises a core-shell nanoparticle tailored according to the operation to be traced. It contains a fluorescent core that allows the detection thereof in the field and a functionalized polymeric shell that provides increased stability in high salinity aqueous phases. A method for preparing said nanotracer. Given the nanotracer versatility, it can be used both for tracing fracking steps as well as meshes of secondary and tertiary recovery.

Abstract: The present invention refers to nanoparticles comprising a core, said core comprising a non-crosslinked albumin matrix and a monoclonal antibody, optionally coated with a non-ionic polymer for use as a medicament, to a pharmaceutical composition comprising said nanoparticles, as well as their use in the treatment of cancer an ocular diseases.

Abstract: An antibacterial compound of formula I, wherein X is selected from fluoro or bromo, effective against Gram negative and Gram positive bacteria, and in particular against non-fermenting multiresistant bacteria affecting patients suffering from cystic fibrosis and which are responsible of severe hospital-acquired infections in immunodepressed patients; its preparation process and pharmaceutical composition comprising said compound.

Abstract: A process for producing propylene glycol from glycerol including a catalyst of Cu and Ce at concentrations of up to 15% of each metal. In addition, it is described a catalyst of Cu and Ce to perform the selective reduction of glycerol and the process of production of such catalyst.

Abstract: The present invention relates to a method of enhancing the activity of a transcription factor in a plant comprising expressing in said plant a chimeric protein comprising a GIF moiety comprising a GIF domain or fragment thereof, and a DNA binding domain (DBD) moiety. The chimeric proteins comprise a GIF moiety comprising a GIF domain or fragment thereof, or a polypeptide with an amino acid sequence having at least 85%, preferably at least 90%, even more preferably at least 95% sequence identity to the amino acid sequence of a GIF domain or fragment thereof; and a DBD moiety comprising the DBD or plant transcription factor whose activity enhancement is intended, or a binding protein which is capable of forming a tertiary complex with the DBD or transcription factor whose activity modification and/or enhancement is intended. The invention also relates to polynucleotides and polypeptides useful in the method of the invention.

Abstract: Method for preventing or treating neuropathic and/or inflammatory pain, wherein said method comprises administering at least one effective dose of the phosphorothioate oligonucleotide IMT504. The preventive method may be applied to a mammal to be subjected to a medical or surgical intervention, or to a mammal that may be injured performing a risky task (for example, a soldier in a battle) to prevent development of pain after a medical intervention or injury.

Abstract: A method for treating a patient suffering from an anti-HER2-resistant, MUC4+ HER2+ cancer is disclosed. For example, the method can be used to treat trastuzumab-resistant HER2+ breast cancer. In some embodiments, the method includes: (i) determining mucin-4 (MUC4) expression in cells of the patient; and (ii) if the MUC4 expression is greater than a predetermined-threshold, administering to the patient a therapeutically effective amount of a selective inhibitor of soluble tumor necrosis factor in combination with an anti-HER2 therapeutic agent, whereby said patient is treated.

Abstract: Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against Shiga toxin (Stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric B subunit of the Shiga 2 toxin fused to the N-terminus of a monomer of Brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides. Polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells having said polynucleotides and vectors, pharmaceutical compositions, such as a vaccine, having said chimeric polypeptides and chimeric polynucleotides, antibodies which bind to the chimeric polypeptides, a method for obtaining antibodies which bind specifically to the subunit B of the Shiga 2 toxin and methods of lowering the bacterial load of enterohemorrhagic Escherichia coli in mammals, which can be used for prevention of inter alia, hemolytic-ureic syndrome (HUS), are also provided.

Abstract: The present invention is directed to an anode for a lithium-ion battery and a method of manufacturing the same. The anode is manufactured from a material composed of Si and C known as SBA-15/C having a porous structure of mesopores interconnected by micropores, wherein carbon nanofibers occupy the pore space of the porous structure. The anode has improved conductivity properties and allows to mitigate the drawbacks linked to the volumetric expansion of the anode during the operation of a lithium-ion battery.

Abstract: A method to determine the activity level of autoimmune diseases, the method including a) to supply a biological sample; b) to determine the TßRII-A, TßRII-B and TßRII-Se isoforms level of the biological sample; c) calculate the activity level by performing the quotient between the TßRII-Se level and the level of the addition of TßRII-A y TßRII-B. The isoforms level are measured by detecting the polypeptides of the isoforms or the mRNA of the isoforms in the isolated circulating mononuclear blood cells by means of, for instance, RT-qPCR. The ?Ct of each splice variants individually showed a correlation with autoimmune disease activity. Additionally, a similar correlation with autoimmune disease activity was obtained when the ?Ct of T?RII-SE was added to the ?Ct of T?RII-A and the ?Ct of T?RII-A.

Abstract: A method for the acid dissolution of LiCoO2 contained in the cathode of lithium ion batteries, using acetic or tartaric acid as leaching agent, the method being characterized in that it comprises a first stage and a second stage, wherein said first stage comprises the step of separating the cathode components, while said second stage comprises the step of dissolving the pure LiCoO2 with at least one acid. The method allows achieving an economically viable complete recycling process with low environmental impact.

Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Abstract: A polynucleotide having at least 80% sequence identity with the full-length nucleotide sequence of SEQ ID NO: 1 and substantially identical polynucleotides; an isolated polypeptide having at least 80% sequence identity with the full-length amino acid sequence of SEQ ID NO: 2 and substantially identical polypeptides; and polynucleotides encoding the Ha WRKY76 polypeptide and substantially identical polypeptides are described. Also described are vectors and recombinant expression cassettes containing the c DNA polynucleotide, a polynucleotide encoding the Ha WRKY76 polypeptide, or substantially identical polynucleotides. Transgenic plants containing such expression cassettes, related methods and uses are also provided.

Abstract: The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and/or interferes with its biological function.

Abstract: A method for controlling an insulin injection device and a system for delivering insulin in a patient in need thereof. The method includes the steps of defining a time interval; receiving the level of blood glucose; computing an insulin dose to be injected in the next time interval, and transmitting the computed insulin dose to be injected to the insulin injection device.

Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.

Abstract: An isoform of the TGF beta receptor II comprising a sequence of about of 80 amino acids and lacking a transmembrane domain; wherein the isoform is a TGF?-1 agonist. The isoform comprises the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2.

Abstract: The present disclosure provides engineered microorganisms, engineered biosynthetic pathways, methods of producing lipid compounds using genetically engineered microorganisms, and the products synthesized by those organisms. In particular, the disclosure provides genetically engineered microorganisms for the production of multi-methyl branched fatty acids (MMBFAs) and MMBFA esters (wax esters) derived from these fatty acids. In addition, the disclosure provides methods for producing acylglycerols with one of more of their acyl substituents being an MMBFA, and methods for producing alcohols derived from MMBFAs (fatty alcohols).

Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.